

Alexander C. Ford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/656134/publications.pdf>

Version: 2024-02-01

522
papers

30,409
citations

3515

90
h-index

5806

161
g-index

547
all docs

547
docs citations

547
times ranked

19311
citing authors

#	ARTICLE	IF	CITATIONS
1	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	2.4	17
2	Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1117-1126.	6.1	115
3	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e923-e944.	2.4	22
4	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14256.	1.6	6
5	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14268.	1.6	4
6	Association of protonâ€pump inhibitor use with adverse health outcomes: A systematic umbrella review of metaâ€analyses of cohort studies and randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1551-1566.	1.1	13
7	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and metaâ€analysis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14279.	1.6	6
8	Bidirectional brainâ€gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1773-1780.	6.1	61
9	Efficacy of <i>Helicobacter pylori</i> eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1967-1975.	6.1	31
10	Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2022, 162, 1752-1754.e1.	0.6	6
11	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. <i>Gut Microbes</i> , 2022, 14, 2028366.	4.3	26
12	Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1311-1319.	1.9	16
13	Relative Contribution of Disease Activity and Psychological Health to Prognosis of Inflammatory Bowel Disease During 6.5 Years of Longitudinal Follow-Up. <i>Gastroenterology</i> , 2022, 163, 190-203.e5.	0.6	17
14	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1976-1987.	6.1	69
15	Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1220-1221.	1.9	0
16	Letter in response to Black <i>et al</i> . (2020): Authorsâ€™ Reply. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14388.	1.6	0
17	Direct healthcare costs of Rome <i>IV</i> or Rome <i>III</i> -defined irritable bowel syndrome in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 110-120.	1.9	37
18	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14391.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Long-Term Impact of Helicobacter pylori Eradication Therapy on Gastric Cancer Incidence and Mortality in Healthy Infected Individuals: A Meta-Analysis Beyond 10 Years of Follow-Up. <i>Gastroenterology</i> , 2022, 163, 754-756.e1.	0.6	9
20	Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1590-1591.	1.9	0
21	Effect of gastroesophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1507-1516.	1.4	13
22	Impact of Rome IV irritable bowel syndrome on work and activities of daily living. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 844-856.	1.9	30
23	Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The Tj ETQq1 1 0.784314 rgBT /Overloc Trials, 2022, 23, .	0.7	4
24	British Society of Gastroenterology guidelines on the management of functional dyspepsia. <i>Gut</i> , 2022, 71, 1697-1723.	6.1	54
25	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 8-21.	1.9	53
26	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1738-1739.	2.4	0
27	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. <i>Gut</i> , 2021, 70, 218.2-219.	6.1	12
28	Best management of irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2021, 12, 303-315.	0.9	25
29	Acceptability of a "treat to target" approach in inflammatory bowel disease to patients in clinical remission. <i>Frontline Gastroenterology</i> , 2021, 12, 30-38.	0.9	7
30	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. <i>Gut</i> , 2021, 70, 644-653.	6.1	76
31	Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. <i>Gut</i> , 2021, 70, 456-463.	6.1	39
32	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gut</i> , 2021, 70, 1110-1116.	6.1	49
33	Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 30-38.	3.7	41
34	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 733-741.	0.6	10
35	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14050.	1.6	25
36	O61...Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. , 2021, , .		2

#	ARTICLE	IF	CITATIONS
37	O63â€¦Gastrointestinal symptom-specific anxiety and symptom severity in irritable bowel syndrome: new insights from factor analysis. , 2021, , .		0
38	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. Journal of Crohn's and Colitis, 2021, 15, 1184-1196.	0.6	26
39	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. Gastroenterology, 2021, 160, 466-467.	0.6	0
40	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. Neurogastroenterology and Motility, 2021, 33, e14070.	1.6	17
41	Satiation or satiety? More than mere semantics â€œ Authors' reply. Lancet, The, 2021, 397, 1061.	6.3	1
42	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 1485-1494.	0.2	24
43	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 2021, 70, 1214-1240.	6.1	212
44	Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. The Lancet Gastroenterology and Hepatology, 2021, 6, 401-410.	3.7	34
45	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	22
46	Psychometric evaluation of an experience sampling methodâ€œbased patientâ€œreported outcome measure in functional dyspepsia. Neurogastroenterology and Motility, 2021, 33, e14136.	1.6	7
47	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 359-370.	3.7	256
48	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloatingâ€œa step in the right direction for targeted treatment? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 198-199.	1.9	0
49	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. Gastroenterology, 2021, 160, 2611-2613.	0.6	3
50	Longitudinal followâ€œup study: effect of psychological coâ€œmorbidity on the prognosis of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 441-450.	1.9	19
51	Irritable bowel syndrome: a spotlight on future research needs. The Lancet Gastroenterology and Hepatology, 2021, 6, 419-422.	3.7	3
52	Systematic review and network metaâ€œanalysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2021, 54, 98-108.	1.9	15
53	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. Scientific Reports, 2021, 11, 15251.	1.6	5
54	A Review of the Evidence and Recommendations on Communication Skills and the Patientâ€œProvider Relationship: AÂ€Rome Foundation Working Team Report. Gastroenterology, 2021, 161, 1670-1688.e7.	0.6	56

#	ARTICLE	IF	CITATIONS
55	AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2481-2488.e1.	2.4	20
56	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1737-1738.	2.4	1
57	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 638-648.	3.7	105
58	Systematic review with meta-analysis: association of <i>Helicobacter pylori</i> infection with gastroesophageal reflux and its complications. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 988-998.	1.9	11
59	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 1865-1877.	0.6	46
60	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. <i>Journal of Psychosomatic Research</i> , 2021, 148, 110561.	1.2	7
61	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 132-139.	0.8	1
62	P326 Identification of novel subgroups in irritable bowel syndrome using latent class analysis: beyond stool form. , 2021, , .		0
63	Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1126-1137.	1.9	17
64	Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach. <i>American Journal of Gastroenterology</i> , 2021, 116, 142-151.	0.2	13
65	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.2	34
66	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021, 116, 372-381.	0.2	43
67	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. <i>Neurogastroenterology and Motility</i> , 2021, , e14282.	1.6	1
68	Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2021, 116, 428-429.	0.2	1
69	Biochemical Tests for Bile Acid Diarrhea: Real-World Studies Required. <i>American Journal of Gastroenterology</i> , 2021, 116, 833-834.	0.2	2
70	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2021, 116, 1352-1353.	0.2	0
71	Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastroesophageal reflux symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 968-976.	1.9	12
72	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	1.9	8

#	ARTICLE	IF	CITATIONS
73	Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 652-653.	1.9	0
74	Editorial: comorbid gastrointestinal conditions are an important consideration in IBS management—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1153-1154.	1.9	0
75	Bloating and Abdominal Distention. , 2020, , 380-385.		0
76	Rational investigations in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020, 11, 140-147.	0.9	14
77	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	6.1	122
78	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1000-1001.	2.4	1
79	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 392-398.e2.	2.4	78
80	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1238-1239.e1.	2.4	47
81	Efficacy of soluble fibre, antispasmodic drugs, and gut—brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	3.7	108
82	Commentary: estimating the prevalence of IBS globally—past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 198-199.	1.9	7
83	Irritable bowel syndrome. <i>Lancet, The</i> , 2020, 396, 1675-1688.	6.3	348
84	Functional gastrointestinal disorders: advances in understanding and management. <i>Lancet, The</i> , 2020, 396, 1664-1674.	6.3	216
85	Functional dyspepsia. <i>Lancet, The</i> , 2020, 396, 1689-1702.	6.3	235
86	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1053-1062.	3.7	109
87	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 908-917.	3.7	359
88	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 762-773.	1.9	29
89	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 923-924.	1.9	7
90	Editorial: minesapride for irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 713-714.	1.9	2

#	ARTICLE	IF	CITATIONS
91	How effective are antibiotics for the treatment of irritable bowel syndrome?. Expert Opinion on Pharmacotherapy, 2020, 21, 2195-2197.	0.9	1
92	Review: Prevention and management of gastric cancer. Helicobacter, 2020, 25, e12740.	1.6	13
93	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13872.	1.6	30
94	Faecal incontinence is not rare in irritable bowel syndrome. Frontline Gastroenterology, 2020, 11, 494.2-496.	0.9	1
95	Practical plus personal: a refreshing approach to careers advice by the British Society of Gastroenterology Taster Course. Frontline Gastroenterology, 2020, 11, 494.1-494.	0.9	1
96	Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2020, 115, 483-484.	0.2	2
97	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut, 2020, 69, 2113-2121.	6.1	231
98	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. The Cochrane Library, 2020, 7, CD005583.	1.5	39
99	Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives. American Journal of Gastroenterology, 2020, 115, 955-956.	0.2	2
100	Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind?. Gastroenterology, 2020, 158, 1508-1510.	0.6	1
101	Polyethylene glycol-based laxatives for chronic constipation – Authors' reply. The Lancet Gastroenterology and Hepatology, 2020, 5, 110-111.	3.7	1
102	Antidepressants in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 184-192.	8.2	47
103	Peppermint Oil in Irritable Bowel Syndrome. Gastroenterology, 2020, 159, 395-396.	0.6	7
104	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut, 2020, 69, 1441-1451.	6.1	137
105	Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 473-486.	8.2	248
106	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. World Journal of Gastroenterology, 2020, 26, 3712-3719.	1.4	17
107	Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2020, 16, 211-213.	0.2	0
108	Assessing the efficacy of peripherally acting μ -opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. Gut, 2019, 68, 1530-1531.	6.1	1

#	ARTICLE	IF	CITATIONS
109	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. <i>Gut</i> , 2019, 68, 434-444.	6.1	49
110	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 632-642.	3.7	186
111	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea—are we any closer?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 825-826.	1.9	1
112	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 517.	0.7	12
113	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 831-844.	3.7	87
114	Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?. <i>Gastroenterology</i> , 2019, 156, 818-820.	0.6	3
115	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 572-573.	2.4	1
116	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13666.	1.6	11
117	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 240-248.	1.9	144
118	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. <i>Gastroenterology</i> , 2019, 156, 2345-2347.	0.6	2
119	Response to Letter by Moulton et al.. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e99-e99.	0.9	0
120	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1254-1255.	1.9	1
121	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231983843.	1.1	11
122	Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882043.	1.4	22
123	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	2.0	81
124	OWE-13...Consequences of using the rome IV criteria to diagnose irritable bowel syndrome. , 2019, , .		0
125	PWE-076...Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
126	Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. <i>Gastroenterology</i> , 2019, 157, 1429-1430.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Relative Efficacy of Naloxegol and Polyethylene Glycol 3350 in Opioid-Induced Constipation. <i>American Journal of Gastroenterology</i> , 2019, 114, 1694-1694.	0.2	1
128	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. <i>BMJ, The</i> , 2019, 367, l6483.	3.0	36
129	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 21-39.	0.2	303
130	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 693-701.	0.6	39
131	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1169-1186.	0.9	63
132	Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13496.	1.6	12
133	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1255-1261.	0.9	36
134	Efficacy of glutamine in postinfection IBS. <i>Gut</i> , 2019, 68, 1905-1906.	6.1	4
135	Clinical Application of Dietary Therapies in Irritable Bowel Syndrome. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 307-316.	0.5	23
136	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. <i>American Journal of Gastroenterology</i> , 2018, 113, 773-774.	0.2	1
137	Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?. <i>Gastroenterology</i> , 2018, 154, 1539-1541.	0.6	1
138	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774473.	1.4	18
139	Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. <i>Cancer Epidemiology</i> , 2018, 54, 137-138.	0.8	0
140	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 700-707.	0.6	35
141	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1597-1605.	0.9	20
142	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 702-712.	0.2	65
143	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 1635-1646.e3.	0.6	258
144	Possible Redundant Data in the Network Meta-analysis of Pharmacological Therapies for Opioid-Induced Constipation. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e8-e9.	0.6	3

#	ARTICLE	IF	CITATIONS
145	Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 140-140.	0.6	0
146	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1165-1167.	2.4	16
147	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2018, 154, 1140-1171.e1.	0.6	247
148	Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13328.	1.6	0
149	Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. <i>Gut</i> , 2018, 67, 430-440.	6.1	397
150	Cyclic vomiting syndrome: a case series and review of the literature. <i>Frontline Gastroenterology</i> , 2018, 9, 2-9.	0.9	17
151	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13174.	1.6	37
152	General practitioners' perceptions of irritable bowel syndrome: a Q-methodological study. <i>Family Practice</i> , 2018, 35, 74-79.	0.8	8
153	Stool as a treatment for IBS: more questions than answers?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 2-3.	3.7	7
154	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. <i>American Journal of Gastroenterology</i> , 2018, 113, 167-169.	0.2	14
155	The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 223-228.	1.1	5
156	Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 39-48.e1.	2.4	29
157	PWE-139...Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. , 2018, , .		0
158	IDDF2018-ABS-0047...Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. , 2018, , .		0
159	Probiotics for Treating Irritable Bowel Syndrome: Are Bugs the Best Drugs?. <i>Gastroenterology</i> , 2018, 155, 2019-2021.	0.6	2
160	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880559.	1.4	23
161	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	1.9	423
162	Fatigue and its associated factors in microscopic colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879959.	1.4	7

#	ARTICLE	IF	CITATIONS
163	Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive Behavioral Therapy. <i>Gastroenterology</i> , 2018, 155, 2024.	0.6	1
164	Young GI angle: How to approach evidence-based medicine. <i>United European Gastroenterology Journal</i> , 2018, 6, 794-795.	1.6	1
165	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	0.6	119
166	Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 837-844.	3.7	37
167	Reply. <i>Gastroenterology</i> , 2018, 155, 1652-1653.	0.6	0
168	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	18.1	235
169	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	21
170	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1-18.	0.2	262
171	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.2	269
172	Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. <i>Medical Journal of Australia</i> , 2018, 209, 86-91.	0.8	108
173	High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878360.	1.4	8
174	Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2018, 113, 1257-1258.	0.2	1
175	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. <i>Gut</i> , 2017, 66, 411-420.	6.1	137
176	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 376-384.e5.	2.4	87
177	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 396-402.	0.6	3
178	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 824-832.	1.9	10
179	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 189-199.	3.7	212
180	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 762-763.	1.9	4

#	ARTICLE	IF	CITATIONS
181	Editorial: volatile organic compounds in irritable bowel syndrome - technology for an accurate and reliable point-of-care test?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 563-564.	1.9	1
182	Editorial: latent class analysis to improve confidence in the diagnosis of <sc>IBS</sc> â€“ authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1268-1269.	1.9	0
183	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. <i>Gastroenterology</i> , 2017, 153, 395-409.e3.	0.6	90
184	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1315-1316.	2.4	0
185	No Detrimental Effect of Oats on Symptoms, Histological Parameters, Serological Tests, or Quality of Life in Celiac Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S481.	0.6	0
186	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1638.	2.4	2
187	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 324-325.	0.6	14
188	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 467-478.	1.1	173
189	Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	22
190	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. <i>Frontline Gastroenterology</i> , 2017, 8, 203-209.	0.9	13
191	Letter: <sc>NICE</sc> referral criteria for lower gastrointestinal alarm features â€“ not ideal but not poor either. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1176-1176.	1.9	0
192	Population screening and treatment of <i>Helicobacter pylori</i> infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 230-240.	8.2	136
193	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2083-2088.	0.9	15
194	De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10852-10857.	3.3	52
195	Use of Probiotics in Hospitalized Adults to Prevent <i>Clostridium difficile</i> Infection: DownGRADE the Quality of Evidence?. <i>Gastroenterology</i> , 2017, 153, 1451-1452.	0.6	3
196	Editorial: probiotics in inflammatory bowel diseaseâ€”wrong organisms, wrong disease, or flawed concepts? Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 633-634.	1.9	0
197	Editorial: subgroups in irritable bowel syndromeâ€”more than just diarrhoea and constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 697-697.	1.9	2
198	Multiple myeloma presenting in association with gastric phytobezoar. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1493-1495.	0.2	3

#	ARTICLE	IF	CITATIONS
199	Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 461-462.	1.9	1
200	Female Gender, Somatization and Presence of IBS-Type Symptoms Predicts Dyspareunia in Patients with IBD. <i>Gastroenterology</i> , 2017, 152, S795.	0.6	0
201	Ongoing Symptoms in Ulcerative Colitis Patients in Remission. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E4-E5.	0.9	6
202	Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.	18.1	203
203	Making a positive diagnosis of irritable bowel syndrome. <i>British Journal of General Practice</i> , 2017, 67, 580-581.	0.7	4
204	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. <i>Gastroenterology</i> , 2017, 153, 1444-1445.	0.6	6
205	Cyclic Vomiting Syndrome: Randomized Controlled Trials Are also Needed in Adults. <i>American Journal of Gastroenterology</i> , 2017, 112, 1752-1753.	0.2	5
206	Irritable Bowel Syndrome. <i>New England Journal of Medicine</i> , 2017, 376, 2566-2578.	13.9	439
207	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 389-400.	1.9	285
208	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 63-74.	1.9	36
209	Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2017, 112, 65-76.	0.2	117
210	Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 91-99.	1.9	11
211	PWE-053—Outcomes of anti-tnf versus vedolizumab therapy for ulcerative colitis: the leeds experience. , 2017, , .		0
212	Pharmacotherapy for Irritable Bowel Syndrome. <i>Journal of Clinical Medicine</i> , 2017, 6, 101.	1.0	33
213	Faecal microbiota transplantation for <i>Clostridium difficile</i> -associated diarrhoea: a systematic review of randomised controlled trials. <i>Medical Journal of Australia</i> , 2017, 207, 166-172.	0.8	109
214	Probiotic <i>Bifidobacterium longum</i> NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 153, 448-459.e8.	0.6	542
215	The possible risks of proton pump inhibitors. <i>Medical Journal of Australia</i> , 2016, 205, 292-293.	0.8	9
216	Evaluation of a faecal calprotectin care pathway for use in primary care. <i>Primary Health Care Research and Development</i> , 2016, 17, 428-436.	0.5	28

#	ARTICLE	IF	CITATIONS
217	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 549-561.	1.9	136
218	Clinical and epidemiological differences in functional dyspepsia between the East and the West. <i>Neurogastroenterology and Motility</i> , 2016, 28, 167-174.	1.6	98
219	Screening for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome: Still a Worthwhile Exercise. <i>Gastroenterology</i> , 2016, 151, 368-370.	0.6	1
220	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> -positive people. <i>The Cochrane Library</i> , 2016, 2016, CD003840.	1.5	112
221	Editorial: Using Patient-Reported Outcome Measures in Gastroenterology: PROMISed Land or Road to Nowhere?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1557-1558.	0.2	2
222	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 75-113.	0.9	25
223	PTU-127...Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. <i>Gut</i> , 2016, 65, A119-A119.	6.1	1
224	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 541-551.	0.2	117
225	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 779.	2.4	0
226	Mo1635 Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. <i>Gastroenterology</i> , 2016, 150, S737-S738.	0.6	0
227	Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. <i>American Journal of Gastroenterology</i> , 2016, 111, 1358.	0.2	3
228	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. <i>Gastroenterology</i> , 2016, 151, 762-763.	0.6	2
229	Pathophysiology of irritable bowel syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 133-146.	3.7	358
230	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. <i>American Journal of Gastroenterology</i> , 2016, 111, 1446-1454.	0.2	41
231	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 440-440.	1.9	1
232	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1246-1246.	1.9	0
233	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1198.	0.2	8
234	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 117-126.	1.9	56

#	ARTICLE	IF	CITATIONS
235	Rome IV criteria for FGIDs “an improvement or more of the same?. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 501-502.	8.2	36
236	Derivation and Validation of a Panel of Exhaled Volatile Organic Compounds in Differentiating Irritable Bowel Syndrome From Health. Gastroenterology, 2016, 151, 1245-1246.	0.6	0
237	Response to Levenstein and Prantera. American Journal of Gastroenterology, 2016, 111, 1499.	0.2	0
238	PTU-128“...Prevalence and Management of Irritable Bowel Syndrome Seen in Colorectal Surgery and Gastroenterology Clinics. Gut, 2016, 65, A120.1-A120.	6.1	0
239	PTU-137“...Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation: Abstract PTU-137 Table 1. Gut, 2016, 65, A125.1-A125.	6.1	0
240	Letter: deleterious effects of smoking on post“operative Crohn's disease “ authors“™ reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 1248-1248.	1.9	0
241	PTU-117“...Screening for Coeliac Disease in Irritable Bowel Syndrome Is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. Gut, 2016, 65, A113.2-A113.	6.1	0
242	Editorial: challenging established perceptions of brain“gut interactions in functional gastrointestinal disorders “ brain“gut, gut“brain, or both?. Alimentary Pharmacology and Therapeutics, 2016, 44, 899-900.	1.9	1
243	Validation and modification of a diagnostic scoring system to predict microscopic colitis. Scandinavian Journal of Gastroenterology, 2016, 51, 1206-1212.	0.6	16
244	Antibiotic use and subsequent development of functional gastrointestinal disorders: effect of symptom-reporting and consultation behavior. Neurogastroenterology and Motility, 2016, 28, 449-450.	1.6	0
245	Ipilimumab-induced colitis: experience from a tertiary referral center. Therapeutic Advances in Gastroenterology, 2016, 9, 457-462.	1.4	31
246	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. American Journal of Gastroenterology, 2016, 111, 900-901.	0.2	1
247	Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2016, 10, 431-442.	1.4	26
248	Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 659-668.e1.	2.4	60
249	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. Clinical Gastroenterology and Hepatology, 2016, 14, 1061-1062.	2.4	5
250	Poor Correlation Between Patient-reported and Endoscopic Components of the Mayo Score in Ulcerative Colitis. Gastroenterology, 2016, 150, 1037-1039.	0.6	4
251	Functional Dyspepsia. New England Journal of Medicine, 2016, 374, 895-896.	13.9	28
252	Validation of a Serum Biomarker for Irritable Bowel Syndrome: Is an Accurate, Single Biomarker Test Possible?. Gastroenterology, 2016, 150, 277-278.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Efficacy of mesalazine in IBS. <i>Gut</i> , 2016, 65, 187.1-188.	6.1	3
254	Functional dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2015, Publish Ahead of Print, 492-8.	1.0	18
255	Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 791-792.	1.9	0
256	Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 781-781.	1.9	1
257	PTU-068 Outcomes of disease modifying therapy delivered to crohn's disease patients following intestinal resection: Abstract PTU-068 Table 1. <i>Gut</i> , 2015, 64, A90.1-A90.	6.1	0
258	Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e116.	1.3	6
259	Symbiotics in irritable bowel syndrome "better than probiotics alone?". <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015, 18, 485-489.	1.3	6
260	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1024-1031.	1.6	18
261	PTU-067 How are postoperative crohn's patients followed up? a retrospective analysis from a tertiary referral centre. <i>Gut</i> , 2015, 64, A89.2-A89.	6.1	0
262	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1227-1236.	1.9	68
263	Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 3-11.	1.9	155
264	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 491-503.	1.9	69
265	Irritable bowel syndrome and somatization. <i>Neurogastroenterology and Motility</i> , 2015, 27, 740-740.	1.6	2
266	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. , 2015, , CD005583.		85
267	PTU-066 Characteristics and outcomes of patients undergoing second intestinal resection for crohn's disease in a tertiary referral centre. <i>Gut</i> , 2015, 64, A89.1-A89.	6.1	0
268	PTU-089 Are clinical indices of inflammatory bowel disease activity superior to patient opinion at predicting activity as defined by faecal calprotectin?: Abstract PTU-089 Table 1. <i>Gut</i> , 2015, 64, A100.1-A100.	6.1	0
269	PTU-090 Prevalence and impact of irritable bowel type-symptoms in quiescent inflammatory bowel disease. <i>Gut</i> , 2015, 64, A100.2-A100.	6.1	0
270	PTU-065 The influence of smoking on need for surgery and post-operative outcomes in crohn's disease. <i>Gut</i> , 2015, 64, A88.2-A89.	6.1	0

#	ARTICLE	IF	CITATIONS
271	IBS-like symptoms in patients with ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 101.	1.0	31
272	PTU-176 Systematic review with meta-analysis: prevalence of bile acid malabsorption in irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2015, 64, A140.2-A141.	6.1	0
273	PTU-086 Outcomes of all surgery for ulcerative colitis over a 12-month period at a tertiary referral ibd unit. <i>Gut</i> , 2015, 64, A98.2-A99.	6.1	0
274	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. <i>American Journal of Gastroenterology</i> , 2015, 110, 1038-1048.	0.2	108
275	Reducing the Need for Random Colonic Biopsies in Patients With Diarrhea. <i>American Journal of Gastroenterology</i> , 2015, 110, 351-352.	0.2	5
276	Combining Biomarkers in Irritable Bowel Syndrome: A Forward Step Toward Making a Positive Diagnosis and Directing Therapy?. <i>Gastroenterology</i> , 2015, 148, 1471-1473.	0.6	2
277	Do Lay People Accept a Positive Diagnosis of Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2015, 149, 252-253.	0.6	3
278	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , 2015, 47, 356-364.	0.4	33
279	Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 816-823.	0.6	69
280	Aetiopathogenesis of functional dyspepsia. <i>Gut</i> , 2015, 64, 1182-1183.	6.1	2
281	Development and Validation of a Scoring System to Identify Patients With Microscopic Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1125-1131.	2.4	39
282	Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1378-1379.	2.4	1
283	Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1548-1549.	2.4	0
284	Comment on "A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [<i>Digestive and Liver Disease</i> 2015;47:119-24]. <i>Digestive and Liver Disease</i> , 2015, 47, 437.	0.4	0
285	Irritable Bowel Syndrome and Colorectal Neoplasia: "Cause and Effect" or Chance Association?. <i>Gastroenterology</i> , 2015, 149, 502-503.	0.6	0
286	Long-term Efficacy and Safety of Azathioprine in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 191-197.	0.6	25
287	Ondansetron and irritable bowel syndrome. <i>Gut</i> , 2015, 64, 1181.1-1181.	6.1	1
288	VSL#3 in Postoperative Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1855.	2.4	1

#	ARTICLE	IF	CITATIONS
289	High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1650-1655.e2.	2.4	73
290	Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. <i>Primary Health Care Research and Development</i> , 2015, 16, 263-269.	0.5	30
291	Lack of Utility of Symptoms and Signs at First Presentation as Predictors of Inflammatory Bowel Disease in Secondary Care. <i>American Journal of Gastroenterology</i> , 2015, 110, 716-724.	0.2	16
292	Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 449-458.	1.9	70
293	Defining the Relationship Between Clinical and Biochemical Disease Activity Indices and Perceived Stress in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1632-1634.	0.6	2
294	Functional Dyspepsia. <i>New England Journal of Medicine</i> , 2015, 373, 1853-1863.	13.9	361
295	Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1222-1223.	1.9	1
296	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e107.	1.3	48
297	Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1944-1945.	2.4	0
298	Central Pain Processing in Irritable Bowel Syndrome Is modulated By Mood: A Mechanism for the Beneficial Effects of Antidepressants?. <i>Gastroenterology</i> , 2015, 148, 247-248.	0.6	2
299	Screening for bile acid diarrhoea in suspected irritable bowel syndrome. <i>Gut</i> , 2015, 64, 851.1-851.	6.1	7
300	Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. <i>Gut</i> , 2015, 64, 1049-1057.	6.1	360
301	Irritable bowel syndrome: dietary interventions. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	2
302	Constipation in adults. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	0
303	<i>Helicobacter pylori</i> eradication: gastric cancer prevention. <i>Clinical Evidence</i> , 2015, 2015, .	0.2	2
304	The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 382-391.	1.9	97
305	Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 216-216.	1.9	2
306	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1981-1990.	2.4	24

#	ARTICLE	IF	CITATIONS
307	Editorial: the overlap of atopy and functional gastrointestinal disorders in primary care - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1244-1245.	1.9	0
308	Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 346-346.	1.9	1
309	PWE-177â€¦A Systematic Review Of Antidepressants In Irritable Bowel Syndrome: A Qualitative Analysis. <i>Gut</i> , 2014, 63, A203.1-A203.	6.1	0
310	Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. <i>Gut</i> , 2014, 63, 703.1-703.	6.1	2
311	Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. <i>Frontline Gastroenterology</i> , 2014, 5, 266-271.	0.9	64
312	Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 312-321.	1.9	87
313	The Rome III Criteria for the Diagnosis of Functional Dyspepsia in Secondary Care Are Not Superior to Previous Definitions. <i>Gastroenterology</i> , 2014, 146, 932-940.e1.	0.6	71
314	Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23,471 primary care patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 827-834.	1.9	30
315	Letter: is there a bi-directional relationship between depression and IBD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 213-213.	1.9	2
316	Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 3-15.	1.9	107
317	Functional Bowel Symptoms in Quiescent Inflammatory Bowel Disease: More Than Just Irritable Bowel Syndrome?. <i>Gastroenterology</i> , 2014, 147, 1176-1177.	0.6	5
318	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.2	595
319	Polyethylene Glycol in Constipation-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2014, 109, 135.	0.2	3
320	The Fall and Rise of 5-Hydroxytryptamine Receptor Antagonists in Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2014, 147, 527-528.	0.6	1
321	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1367-1374.	0.2	258
322	Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 683-691.	8.2	47
323	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.2	503
324	Whom should we "test and treat" for <i>Helicobacter pylori</i> ?. <i>BMJ</i> , The, 2014, 348, g3320-g3320.	3.0	8

#	ARTICLE	IF	CITATIONS
325	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 447-458.	1.9	144
326	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.2	335
327	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i> , 2014, 348, g3174-g3174.	3.0	477
328	Masquerading Gastrointestinal Polyps: Air on the Side of Caution?. <i>Gastroenterology</i> , 2014, 146, e9-e10.	0.6	5
329	Diagnosing Irritable Bowel Syndrome With a Combination of Biomarkers and Psychomarkers. <i>Gastroenterology</i> , 2014, 146, 1418-1420.	0.6	1
330	Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 375-383.	0.6	13
331	PWE-098...Earlier Use Of Azathioprine In Ulcerative Colitis Does Not Alter Subsequent Need For Hospitalisation, Biologic Therapy, Or Colectomy. <i>Gut</i> , 2014, 63, A167.1-A167.	6.1	0
332	PTU-075...Systematic Review And Meta-analysis: Sensitivity And Specificity Of Tc-99m Hmpao Labelled White Cell Scintigraphy In The Diagnosis Of Active Inflammatory Bowel Disease. <i>Gut</i> , 2014, 63, A71.2-A71.	6.1	2
333	PWE-185...Beliefs About Management Of Irritable Bowel Syndrome In Primary Care: Cross-sectional Survey: Abstract PWE-185 Table 1. <i>Gut</i> , 2014, 63, A207.1-A207.	6.1	0
334	PTH-106...Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study. <i>Gut</i> , 2014, 63, A257.2-A258.	6.1	0
335	Death Knell for Placebo-Controlled Trials in Chronic Idiopathic Constipation?. <i>Gastroenterology</i> , 2013, 145, 897-898.	0.6	3
336	Bathyal demersal fishes of Charlie-Gibbs Fracture Zone region (49°54'N) of the Mid-Atlantic Ridge: II. Baited camera lander observations. <i>Deep-Sea Research Part II: Topical Studies in Oceanography</i> , 2013, 98, 397-406.	0.6	15
337	Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. <i>Gastroenterology</i> , 2013, 145, 1262-1270.e1.	0.6	163
338	Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1566-1574.	0.2	92
339	Prevalence of Irritable Bowel Syndrome-type Symptoms in Patients With Celiac Disease: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 359-365.e1.	2.4	141
340	A Patient With Chronic Diarrhea of Unknown Cause. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, e27-e28.	2.4	0
341	First-line Eradication Therapy for <i>Helicobacter pylori</i> : Time for a Change?. <i>Gastroenterology</i> , 2013, 144, 652-653.	0.6	2
342	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 853-867.	0.6	168

#	ARTICLE	IF	CITATIONS
343	Reply. Clinical Gastroenterology and Hepatology, 2013, 11, 102-103.	2.4	2
344	NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Alimentary Pharmacology and Therapeutics, 2013, 37, 195-203.	1.9	45
345	The natural history of gastroesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. Alimentary Pharmacology and Therapeutics, 2013, 37, 323-331.	1.9	23
346	Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians. Neurogastroenterology and Motility, 2013, 25, 89-89.	1.6	9
347	Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. American Journal of Gastroenterology, 2013, 108, 894-903.	0.2	62
348	Opportunistic Infections With Anti-Tumor Necrosis Factor- α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2013, 108, 1268-1276.	0.2	295
349	Ulcerative colitis. BMJ, The, 2013, 346, f432-f432.	3.0	122
350	Dyspepsia. BMJ, The, 2013, 347, f5059-f5059.	3.0	12
351	Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. Therapeutic Advances in Chronic Disease, 2013, 4, 268-276.	1.1	7
352	Don't forget about constipation with opioid treatment of chronic non-cancer pain. BMJ, The, 2013, 347, f4492-f4492.	3.0	0
353	Dyspepsia. Current Opinion in Gastroenterology, 2013, 29, 662-668.	1.0	18
354	Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut, 2013, 62, 653.1-653.	6.1	5
355	Response to Neis et al.. American Journal of Gastroenterology, 2013, 108, 1930.	0.2	1
356	Initial management of dyspepsia in primary care: an evidence-based approach. British Journal of General Practice, 2013, 63, 498-499.	0.7	11
357	PTH-084...Endoscopic and Histological Activity as Predictors of Relapse in Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis: Abstract PTH-084 Table 1. Gut, 2013, 62, A245.2-A245.	6.1	0
358	PTU-136...Prevalence of Functional Gastrointestinal Disorders in Consecutive New Patient Referrals to a Gastroenterology Clinic: Abstract PTU-136 Table 1. Gut, 2013, 62, A102.2-A103.	6.1	0
359	PTH-194...A Retrospective Analysis of Glucose-Hydrogen Breath test for Small Intestine Bacterial Overgrowth in a Teaching Hospital. Gut, 2013, 62, A290.2-A291.	6.1	0
360	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. The Cochrane Library, 2013, , CD008337.	1.5	120

#	ARTICLE	IF	CITATIONS
361	PWE-153â€¦Associationâ€¦Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. <i>Gut</i> , 2013, 62, A193.2-A193.	6.1	0
362	PTH-199â€¦Prevalence of Organic Disorders in Consecutive New Patients Meeting Criteria for IBS in a Gastroenterology Clinic. <i>Gut</i> , 2013, 62, A292.3-A293.	6.1	0
363	Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. <i>World Journal of Gastroenterology</i> , 2013, 19, 1091.	1.4	24
364	In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents. <i>Evidence-Based Medicine</i> , 2012, 17, 114-115.	0.6	4
365	Laxatives for chronic constipation in adults. <i>BMJ, The</i> , 2012, 345, e6168-e6168.	3.0	15
366	Direction of the brainâ€“gut pathway in functional gastrointestinal disorders. <i>Gut</i> , 2012, 61, 1368.1-1368.	6.1	5
367	Effect of Dyspepsia on Survival: A Longitudinal 10-Year Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 912-921.	0.2	74
368	Effect of Gender on Prevalence of Irritable Bowel Syndrome in the Community: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 991-1000.	0.2	320
369	Response to Doherty and Moss. <i>American Journal of Gastroenterology</i> , 2012, 107, 487-488.	0.2	0
370	Response to Kayhan et al.. <i>American Journal of Gastroenterology</i> , 2012, 107, 321-322.	0.2	0
371	OC-151â€¦Prevalence of, and predictors of, a positive SEHCAT scan for bile acid diarrhoea in outpatients with chronic diarrhoea. <i>Gut</i> , 2012, 61, A65.2-A65.	6.1	0
372	PWE-059â€¦Prevalence of gastro-esophageal reflux disease in individuals with irritable bowel syndrome: a systematic review and meta-analysis: Abstract PWE-059 Table 1. <i>Gut</i> , 2012, 61, A321.1-A321.	6.1	0
373	PWE-060â€¦Effect of gender on prevalence and subtype of irritable bowel syndrome: a systematic review and meta-analysis. <i>Gut</i> , 2012, 61, A321.2-A321.	6.1	0
374	Treatment of <i>Helicobacter pylori</i> in Latin America. <i>Lancet, The</i> , 2012, 379, 407.	6.3	0
375	Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 167-176.	0.2	130
376	Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 513-519.	2.4	44
377	Irritable bowel syndrome. <i>BMJ, The</i> , 2012, 345, e5836-e5836.	3.0	72
378	Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1474-1482.	0.2	475

#	ARTICLE	IF	CITATIONS
379	Eradicating Helicobacter Pylori in Functional Dyspepsia. <i>Gastroenterology</i> , 2012, 142, 1613-1614.	0.6	10
380	Acupuncture for Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2012, 143, 1683-1684.	0.6	6
381	Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 143-153.	0.6	116
382	Prevalence of Gastro-Esophageal Reflux-Type Symptoms in Individuals With Irritable Bowel Syndrome in the Community: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1793-1801.	0.2	79
383	Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 712-721.e4.	2.4	1,624
384	Incidental focal colonic lesions found on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. <i>Colorectal Disease</i> , 2012, 14, e56-63.	0.7	17
385	Hypertransaminasaemia and coeliac disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 203-204.	1.9	0
386	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 284-291.	1.9	19
387	Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 207-207.	1.9	1
388	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. <i>Neurogastroenterology and Motility</i> , 2012, 24, 983.	1.6	84
389	Irritable bowel syndrome. <i>Clinical Evidence</i> , 2012, 2012, .	0.2	7
390	Evidence-based management of ulcerative colitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2012, 58, 87-99.	2.2	6
391	Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, 209-218.	6.1	312
392	Advances in pathophysiology, diagnosis and treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 76-78.	8.2	24
393	Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 661-673.	0.2	469
394	Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: the More Things Change, the More They Stay the Same. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 87-103.	1.0	16
395	Medical or Surgical Therapy for Gastroesophageal Reflux Disease?. <i>Gastroenterology</i> , 2011, 141, 1938-1939.	0.6	1
396	Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 324-331.	0.6	23

#	ARTICLE	IF	CITATIONS
397	Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1582-1591.	0.2	645
398	Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 644-659.	0.2	523
399	Efficacy of Traditional Chinese Medicine in Functional Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1003.	0.2	7
400	Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 617-629.	0.2	170
401	Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 590-599.	0.2	266
402	ROME III Criteria for Functional Gastrointestinal Disorders: Too Much Overlap to Be Useful?. <i>Gastroenterology</i> , 2011, 140, S-725-S-726.	0.6	3
403	Chemoprevention for gastric cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 581-592.	1.0	23
404	VSL#3 and Remission in Active Ulcerative Colitis: Larger Studies Required. <i>American Journal of Gastroenterology</i> , 2011, 106, 547.	0.2	6
405	<i>Helicobacter pylori</i> eradication. <i>Lancet, The</i> , 2011, 378, 313.	6.3	0
406	Coeliac disease and hypertransaminasaemia: a systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A18-A18.	6.1	0
407	Efficacy of tegaserod for the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A154-A154.	6.1	0
408	Efficacy of lubiprostone in the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A164-A165.	6.1	0
409	Efficacy of prucalopride in the treatment of chronic idiopathic constipation: systematic review and meta-analysis. <i>Gut</i> , 2011, 60, A154-A154.	6.1	1
410	Predictors of response and loss of response to infliximab therapy for crohn's disease: a large UK single centre experience. <i>Gut</i> , 2011, 60, A218-A218.	6.1	0
411	Low Yield of Colonoscopy for Melaena Following a Normal Upper Gastrointestinal Endoscopy: A 5-year Analysis. <i>Gut</i> , 2011, 60, A127-A127.	6.1	0
412	Adverse events associated with infliximab therapy in a large single centre UK cohort. <i>Gut</i> , 2011, 60, A217-A218.	6.1	0
413	Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression. <i>Gut</i> , 2011, 60, A154-A155.	6.1	2
414	Defining a responder in treatment trials for chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 285-286.	1.9	2

#	ARTICLE	IF	CITATIONS
415	Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis: authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 289-289.	1.9	0
416	Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 498-498.	1.9	0
417	Systematic review: the effects of fibre in the management of chronic idiopathic constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 895-901.	1.9	211
418	Do dried plums really help constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1258-1259.	1.9	1
419	Meta-analysis: coeliac disease and hypertransaminasaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 33-40.	1.9	76
420	Meta-analysis: the epidemiology of noncardiac chest pain in the community. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 172-180.	1.9	44
421	Is otilonium bromide globally effective in irritable bowel syndrome?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1034-1035.	1.9	2
422	Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. <i>Journal of Gastroenterology</i> , 2011, 46, 421-431.	2.3	166
423	5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 413-420.	0.2	91
424	Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 115-127.	1.4	26
425	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 601-616.	0.2	231
426	Losses to Follow-Up Limit Conclusions Regarding the Efficacy of Branched-Chain Amino Acids in Patients With Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2011, 106, 1718.	0.2	1
427	Response to Atreja et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2046.	0.2	0
428	Response to Yang et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2044.	0.2	0
429	Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 630-642.	0.2	212
430	Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2070-2077.	0.2	52
431	Reply to Akobeng. <i>American Journal of Gastroenterology</i> , 2011, 106, 1857-1858.	0.2	0
432	Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful?. <i>Gut</i> , 2011, 60, A25-A25.	6.1	0

#	ARTICLE	IF	CITATIONS
433	Utility of Fecal Calprotectin in Differentiating Active Inflammatory Bowel Disease From Coexistent Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 166.	0.2	5
434	PWE-038â€¦Adalimumab therapy for infliximab failures in Crohn's disease. A single-centre UK experience. <i>Gut</i> , 2010, 59, A99.3-A100.	6.1	0
435	PTU-055â€¦Safety and tolerability of combination therapy for chronic hepatitis C: the Leeds experience: Abstract PTU-055. <i>Gut</i> , 2010, 59, A71.1-A71.	6.1	0
436	PTU-057â€¦Predictors of response to combination therapy for chronic hepatitis C: the Leeds experience. <i>Gut</i> , 2010, 59, A71.3-A72.	6.1	0
437	Epidemiology of <i>Helicobacter pylori</i> infection and Public Health Implications. <i>Helicobacter</i> , 2010, 15, 1-6.	1.6	146
438	Is the Benefit of Granulocyte Monocyte Adsorptive Apheresis in Ulcerative Colitis Overstated?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1803-1804.	1.1	3
439	Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 161-162.	1.9	4
440	Alverine citrate, simeticone, and Rome III irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 767-768.	1.9	3
441	Probiotics in irritable bowel syndrome: underachievers or underpowered?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 922-923.	1.9	5
442	Renzapride in IBS: is efficacy in the eye of the beholder?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 113-114.	1.9	3
443	Systematic review: prognostic tests of paracetamolâ€nduced acute liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1064-1076.	1.9	76
444	Metaâ€nalysis: factors affecting placebo response rate in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 144-158.	1.9	185
445	Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 612-613.	1.9	2
446	Reporting of relapse rates in a trial of mesalazine for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1205-1206.	1.9	1
447	Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1294-1295.	1.9	3
448	Costs of care for Crohnâ€™s disease following the introduction of infliximab: a singleâ€centre UK experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1357-1363.	1.9	32
449	Effect of oral zinc in hepatic encephalopathy remains unclear. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1405-1406.	1.9	4
450	Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1297-1306.	1.9	46

#	ARTICLE	IF	CITATIONS
451	PTU-056â€¦Efficacy of combination therapy for chronic hepatitis C: the Leeds experience. Gut, 2010, 59, A71.2-A71.	6.1	0
452	Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. Gut, 2010, 59, 1731-1732.	6.1	3
453	Errors in the Conduct of Systematic Reviews of Pharmacological Interventions for Irritable Bowel Syndrome. American Journal of Gastroenterology, 2010, 105, 280-288.	0.2	45
454	Low Yield of Colonoscopy in Individuals With Suspected Irritable Bowel Syndrome?. American Journal of Gastroenterology, 2010, 105, 2508-2509.	0.2	0
455	Overlap Among the Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2010, 105, 2512.	0.2	4
456	What Is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2010, 8, 830-837.e2.	2.4	166
457	Systematic Review and Meta-analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia. Clinical Gastroenterology and Hepatology, 2010, 8, 401-409.	2.4	173
458	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut, 2010, 59, 325-332.	6.1	588
459	The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice. Gastroenterology, 2010, 138, 789-791.	0.6	7
460	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. Gastroenterology, 2010, 138, 1727-1736.	0.6	75
461	Disease activity and venous thromboembolism in inflammatory bowel disease. Lancet, The, 2010, 375, 1690.	6.3	0
462	â€œPowerâ€•of Selective Serotonin Reuptake Inhibitors in Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2010, 8, 313-314.	2.4	2
463	Breath testing and antibiotics for possible bacterial overgrowth in irritable bowel syndrome. Expert Review of Anti-Infective Therapy, 2010, 8, 855-857.	2.0	2
464	Determining the Optimum Outcome for Trials Evaluating Symptom Improvement in Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2010, 105, S492-S493.	0.2	0
465	Irritable bowel syndrome. Clinical Evidence, 2010, 2010, .	0.2	1
466	Is laparoscopic surgery cost-effective?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 695-696.	8.2	0
467	Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2009, 104, 1831-1843.	0.2	235
468	Yield of Diagnostic Tests for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome. Archives of Internal Medicine, 2009, 169, 651.	4.3	216

#	ARTICLE	IF	CITATIONS
469	Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 71-75.	0.8	39
470	Treatment of chronic gastro-oesophageal reflux disease. <i>BMJ: British Medical Journal</i> , 2009, 339, b2481-b2481.	2.4	4
471	Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel Syndrome—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1126.	3.8	1
472	Managing dyspepsia. <i>Current Gastroenterology Reports</i> , 2009, 11, 288-294.	1.1	10
473	10-Åbiomarker algorithm to identify irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 95-96.	1.9	4
474	Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 28-36.	1.9	52
475	Generalized anxiety disorder and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1087-1088.	1.9	2
476	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1279-1286.	2.4	306
477	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009, 58, 367-378.	6.1	486
478	Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1805.	0.7	8
479	Redundant Data in the Meta-analysis on <i>Helicobacter pylori</i> Eradication. <i>Annals of Internal Medicine</i> , 2009, 151, 513.	2.0	18
480	Does <i>Helicobacter pylori</i> really cause duodenal ulcers? Yes. <i>BMJ: British Medical Journal</i> , 2009, 339, b2784-b2784.	2.4	6
481	Bran's deleterious effects: much ado about nothing. <i>BMJ: British Medical Journal</i> , 2009, 339, b3956-b3956.	2.4	1
482	Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care?. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 391-396.	0.3	3
483	<i>Helicobacter pylori</i> infection. <i>Clinical Evidence</i> , 2009, 2009, .	0.2	2
484	Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care?. , 2009, 119, 391-6.		2
485	Management of irritable bowel syndrome. <i>Minerva Gastroenterologica E Dietologica</i> , 2009, 55, 273-87.	2.2	4
486	Meta-analysis: <i>Helicobacter pylori</i> test and treatment™ compared with empirical acid suppression for managing dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 534-544.	1.9	49

#	ARTICLE	IF	CITATIONS
487	Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1013-1020.	1.9	51
488	<i>Helicobacter pylori</i> test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). <i>BMJ: British Medical Journal</i> , 2008, 336, 651-654.	2.4	81
489	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. <i>Gut</i> , 2008, 57, 1545-1553.	6.1	124
490	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a2313-a2313.	2.4	454
491	Current Guidelines for Dyspepsia Management. <i>Digestive Diseases</i> , 2008, 26, 225-230.	0.8	34
492	Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior. <i>American Journal of Gastroenterology</i> , 2008, 103, 1229-1239.	0.2	194
493	Balancing the risk of chronic gastrointestinal bleeding and thromboembolic events in a patient with a metallic aortic valve. <i>Clinical Medicine</i> , 2008, 8, 461-462.	0.8	0
494	Will the History and Physical Examination Help Establish That Irritable Bowel Syndrome Is Causing This Patient's Lower Gastrointestinal Tract Symptoms?. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1793.	3.8	98
495	Adverse events with bismuth salts for <i>Helicobacter pylori</i> eradication: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7361.	1.4	107
496	Utility of Diagnostic Tests for Celiac Disease in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S463.	0.2	2
497	Efficacy of Antidepressants in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S476-S477.	0.2	2
498	Efficacy of 5HT4-Agonists in Non-Diarrhea Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S478.	0.2	1
499	The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2008, 103, S481.	0.2	9
500	Who Consults With Dyspepsia? Results from a Longitudinal 10-Yr Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 957-965.	0.2	65
501	Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. <i>Gut</i> , 2007, 56, 321-327.	6.1	96
502	Effect of sibling number in the household and birth order on prevalence of <i>Helicobacter pylori</i> : a cross-sectional study. <i>International Journal of Epidemiology</i> , 2007, 36, 1327-1333.	0.9	31
503	Electronic Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2007, 133, e3-e4.	0.6	0
504	Mycophenolate mofetil therapy for refractory inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1488-1492.	0.9	35

#	ARTICLE	IF	CITATIONS
505	The Short-Form Leeds Dyspepsia Questionnaire validation study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 477-486.	1.9	73
506	Clinical trial: knowledge of negative <i>Helicobacter pylori</i> status reduces subsequent dyspepsia-related resource use. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1267-1275.	1.9	11
507	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. , 2006, , CD003840.		85
508	Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. <i>Thorax</i> , 2006, 61, 975-979.	2.7	204
509	Initial management strategies for dyspepsia. , 2005, , CD001961.		63
510	Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1483-1490.	1.9	80
511	Ethnicity, Gender, and Socioeconomic Status as Risk Factors for Esophagitis and Barrett's Esophagus. <i>American Journal of Epidemiology</i> , 2005, 162, 454-460.	1.6	143
512	<i>Helicobacter pylori</i> "Test and Treat" or Endoscopy for Managing Dyspepsia: An Individual Patient Data Meta-analysis. <i>Gastroenterology</i> , 2005, 128, 1838-1844.	0.6	122
513	Image of the Month. <i>Gastroenterology</i> , 2005, 129, 785.	0.6	1
514	A Community Screening Program for <i>Helicobacter pylori</i> Saves Money: 10-Year Follow-up of a Randomized Controlled Trial. <i>Gastroenterology</i> , 2005, 129, 1910-1917.	0.6	65
515	Eradication Therapy in <i>Helicobacter pylori</i> Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1833-1855.	0.2	155
516	The Natural History of Sporadic Duodenal Adenomas and Risk of Synchronous Colonic Adenomas. <i>Gastrointestinal Endoscopy</i> , 2004, 59, P170.	0.5	0
517	Mycophenolate mofetil in refractory inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1365-1369.	1.9	26
518	Recent developments in gastroenterology. <i>BMJ: British Medical Journal</i> , 2002, 325, 1399-1402.	2.4	15
519	Image of the month. <i>Gastroenterology</i> , 2002, 122, 1720.	0.6	1
520	Immunologic distribution of an organic anion transport protein in rat liver and kidney. <i>American Journal of Physiology - Renal Physiology</i> , 1996, 271, G231-G238.	1.6	80
521	Global Prevalence of Chronic Idiopathic Constipation According to the Rome Criteria: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
522	Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0